en.Wedoany.com Reported - Brand Engagement Network, Inc. (Nasdaq: BNAI, referred to as BEN) announced that the clinical evaluation project for the AI-powered medical evidence platform Skye Salud, developed in collaboration with partners, has entered its second phase in Mexico. This project aims to assess the role of AI-driven access to credible medical evidence in improving the accessibility of clinical information.
Skye Salud, jointly created by BEN, Grupo Skye, and KNOBLOCH Information Group, is an AI-based medical evidence platform. It leverages authoritative sources such as peer-reviewed literature and clinical guidelines to support evidence-based clinical information retrieval. The project integrates BEN's enterprise-grade AI capabilities, Grupo Skye's influence in AI innovation in Latin America, and KNOBLOCH Information Group's long-standing relationships and professional insights within the Mexican healthcare community.
The launch of the Phase II evaluation builds on the success of Phase I testing in rheumatology. Phase I primarily assessed the platform's performance in specialty-specific clinical scenarios, including metrics such as evidence traceability, response quality, and source transparency. Based on Phase I results, Phase II expands the testing scope to primary care use cases, evaluating the platform's performance across a broader range of clinical topics and physician information needs. To this end, the evaluation incorporates Spanish-language clinical content optimized for the Mexican healthcare environment.
Mexico, as one of the largest healthcare markets in Latin America, provides a significant setting for large-scale evaluation of such AI platforms. Expanding the evaluation to primary care aims to gain further insights into platform performance, content coverage, usability, and future development opportunities. This evaluation plan reflects BEN's strategic direction in developing enterprise-grade AI solutions for regulated industries, emphasizing accuracy, transparency, accountability, and human involvement.
The Phase I rheumatology testing was guided by Dr. Ruy Carrasco, Chief Medical Information Officer of Skye Salud and a member of the BEN Board of Directors. Tyler Luck, CEO of BEN, stated that the completion of Phase I testing provided valuable insights into the platform's performance, evidence traceability, and response quality in rheumatology use cases. He noted that entering Phase II will assess the platform's performance across a wider range of clinical questions. Dr. Ruy Carrasco believes that the initial pilot in rheumatology validated the platform's response architecture, and expanding it to primary care will stress-test performance metrics without lowering the evidence thresholds and source transparency protocols established in Phase I testing.
The Phase II primary care evaluation aims to assess the platform's clinical coverage and evidence support capabilities, providing a basis for future product development and commercialization planning. Depending on future evaluation results, regulatory factors, and commercial agreements, partners including BEN, Grupo Skye, and KNOBLOCH Information Group may explore expanding clinical coverage, extending Spanish-language medical content, and evaluating the platform's potential applications in the healthcare environments of Mexico and Latin America.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
